LAKE FOREST, CA – June 12, 2014 — Cryoport, Inc. (OTC BB: CYRX) ("the Company"), the leading provider of advanced cryogenic logistics solutions, today announced that it will be showcasing its patented Cryoport Express® Shippers and its Cryoportal™ Logistics Management Platform, a revolutionary, purpose-built technology which manages and monitors the entire cold chain logistics process for biologic materials, at the BioLogistics Summit in San Diego, California, on June 16th-18th.
Cold Chain IQ, a division of IQPC, presents the Cold Chain BioLogistics Summit in order to tackle the key challenges associated with handling, storing, manufacturing and distributing biologics. The two-track event will focus on maintaining regulatory compliant transportation and management of biological materials, clinical specimens and infectious substances.
Cryoport’s Chief Commercial Officer, Steven Leatherman will be on-site at booth number 2, exhibiting Cryoport’s cryogenic logistics solutions including the Cryoportal™. The Cryoportal™ platform provides a focused solution to key conference topics, such as ensuring quality cold chain supply and temperature management, avoiding extra costs for clinical trial delays, the benefits of a partly outsourced supply chain model and many other logistics matters.
Due to the growing complexities and rapid changes in the global life science logistics industry, coupled with the increasing demand for consistent and reliable logistics solutions, more and more life science companies are outsourcing non-core competencies such as logistics. With the obligation of abiding by stringent regulatory guidelines and rising costs, sound logistics solutions are more critical than ever for life science companies.
“We are pleased to participate in Cold Chain IQ’s BioLogistics Summit and exhibit our cryogenic logistics solutions to its wide range of attendees from the life sciences community around the world,” stated Jerrell Shelton, Chief Executive Officer of Cryoport. “This event specifically targets the cold chain challenges facing the fast-growing and evolving life sciences industry. As such, our advanced proprietary logistics solutions are expected to be of great interest to those in attendance, as Cryoport ensures the uncompromised, safe and timely delivery of biologic materials using our validated and easy-to-use cryogenic logistics solutions.”
IQPC is an industry-recognized leader in B2B temperature control pharmaceutical events for 12 years across the North America and the world in new and emerging markets. Today there are 13 IQPC cold chain pharmaceutical events around the world. The flagship IQPC Cold Chain Global Forum each September brings 600+ supply chain stakeholders together to discuss today's hottest topics in temperature control logistics and quality management. Online we continue engaging and educating the temperature control biopharma industry on http://www.coldchainiq.com – a free resource center of articles, videos and expert interviews.
About Cryoport, Inc.
Cryoport provides leading edge cryogenic logistics solutions to the life sciences industry through the combination of purpose-built proprietary packaging, advanced information technology and highly skilled logistics expertise which manages the entire cold chain logistics process. Cryoport Express® liquid nitrogen dry vapor shippers are validated to maintain a constant -150°C temperature for a 10-plus day dynamic shipment duration, and its Cryoportal™ Logistics Management Platform assists in managing the entire logistics process, including initial order input, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery. Cryoport’s total turnkey logistics solutions offer reliability, cost effectiveness, and convenience, while the use of recyclable and reusable components provides a “green” and environmentally friendly solution. Cryoport service options include recording the “chain of condition” and “chain of custody” for all shipments thereby meeting the exacting requirements for scientific work and for regulatory purposes. For more information visit www.cryoport.com.
Forward Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise, any forward-looking statements in this press release.